{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:31Z","timestamp":1790775511846,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2022-CC125163"],"award-info":[{"award-number":["RS-2022-CC125163"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001255","name":"National Cancer Coalition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jhep.2025.08.020","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:11:00Z","timestamp":1757031060000},"page":"308-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-0642","authenticated-orcid":false,"given":"Hyung-Don","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Sym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong-kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyewon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.08.020_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.08.020_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.08.020_bib3","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.08.020_bib4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.08.020_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.021","article-title":"Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients","volume":"189","author":"Persano","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.08.020_bib6","first-page":"1","article-title":"Real-world study of systemic treatment after first-line atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries","author":"Lee","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.08.020_bib7","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.3390\/cancers15235532","article-title":"Real-world systemic treatment patterns after atezolizumab and bevacizumab in patients with hepatocellular carcinoma in the United States","volume":"15","author":"Singal","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jhep.2025.08.020_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000512781","article-title":"Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study","volume":"10","author":"Yoo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.08.020_bib9","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.020_bib10","doi-asserted-by":"crossref","DOI":"10.1159\/000541018","article-title":"Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study","author":"Persano","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2025.08.020_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.020_bib12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","article-title":"Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","volume":"81","author":"Chan","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.020_bib13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000543666","article-title":"Multicenter phase 2 trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on atezolizumab plus bevacizumab (REGONEXT)","volume":"14","author":"Cheon","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.08.020_bib14","series-title":"International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI)","author":"El-Khoueiry","year":"2024"},{"key":"10.1016\/j.jhep.2025.08.020_bib15","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.08.020_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3350\/cmh.2023.0553","article-title":"Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab\/bevacizumab failure: a real-world study","volume":"30","author":"Chon","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.08.020_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2022.09.006","article-title":"Overall survival and objective response in advanced unresectable hepatocellular carcinoma: a subanalysis of the REFLECT study","volume":"78","author":"Kudo","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.020_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.020_bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/liv.13359","article-title":"mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomised phase II trials comparing nintedanib vs sorafenib","volume":"37","author":"Meyer","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.08.020_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.08.020_bib21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s11523-024-01103-7","article-title":"Impact of etiology on efficacy outcomes with atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational retrospective analysis in Asia-Pacific","volume":"19","author":"Kim","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.jhep.2025.08.020_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.24406","article-title":"Clinical trial evidence supporting US Food and drug Administration approval of Novel Cancer therapies between 2000 and 2016","volume":"3","author":"Ladanie","year":"2020","journal-title":"JAMA Netw Open"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2026.05.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000}},{"DOI":"10.1016\/j.jhep.2026.05.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825024572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825024572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:47:30Z","timestamp":1774554450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825024572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0168827825024572"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.08.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}